{
    "clinical_study": {
        "@rank": "115910", 
        "arm_group": [
            {
                "arm_group_label": "Sirolimus", 
                "arm_group_type": "Active Comparator", 
                "description": "Conversion from Tacrolimus to Sirolimus"
            }, 
            {
                "arm_group_label": "Tacrolimus", 
                "arm_group_type": "Active Comparator", 
                "description": "Maintenance on tacrolimus"
            }
        ], 
        "brief_summary": {
            "textblock": "Background Early conversion from calcineurin inhibitor to mammalian target of rapamycin\n      inhibitor is one of the immunosuppressive strategies that have been investigated to mitigate\n      long-term CNi associated adverse events. This study aims to evaluate the conversion from\n      tacrolimus to sirolimus in de novo kidney transplant recipients.\n\n      This multicenter, open-label study, planned to enroll 297 patients initially treated with\n      tacrolimus, enteric-coated mycophenolate sodium (1440 mg/day, orally) and prednisone. The\n      primary objective is to show superior glomerular filtration rate in the SRL group at 24\n      months after transplantation."
        }, 
        "brief_title": "Planned Conversion From TAC to SRL-based Regimen in de Novo Kidney Transplant Recipients", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Kidney Transplant", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients older than 18 years,\n\n          -  recipients of first kidney transplant from brain dead deceased or living related\n             non-HLA identical donors not older than 65 years,\n\n          -  patients had to receive an ABO compatible organ with a CDC negative crossmatch and a\n             peak panel reactive antibody lower that 30%,\n\n          -  all patients agreed to use contraceptive methods during the study and up to 3 months\n             after study drug discontinuation.\n\n        Exclusion Criteria:\n\n          -  patients with chronic kidney diseases due to focal and segmental glomerulosclerosis\n             and membranoproliferative glomerulonephritis,\n\n          -  patients with active infection or positive for hepatitis B or C or human\n             immunodeficiency viruses,\n\n          -  patients with previous history of malignancy,\n\n          -  patients with significant hematological or metabolic laboratorial abnormalities."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "320", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01802268", 
            "org_study_id": "0468E8-3328"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sirolimus", 
                "intervention_name": "Conversion from Tacrolimus to Sirolimus", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tacrolimus", 
                "intervention_name": "Maintenance on tacrolimus", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Sirolimus", 
                "Everolimus", 
                "Tacrolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "sirolimus", 
            "tacrolimus", 
            "early conversion"
        ], 
        "lastchanged_date": "February 27, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Curitiba", 
                        "country": "Brazil", 
                        "state": "Paran\u00e1"
                    }, 
                    "name": "Hospital University Evang\u00e9lico de Curitiba, Curitiba, Parana, Brazil"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil", 
                        "state": "Rio Grande do Sul"
                    }, 
                    "name": "Kidney & Pancreas Transplant Unit, Santa Casa de Misericordia, Porto Alegre, Brazil"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "S\u00e3o Jose do Rio Preto", 
                        "country": "Brazil", 
                        "state": "S\u00e3o Paulo", 
                        "zip": "04038"
                    }, 
                    "name": "Instituto de Urologia e Nefrologia & Medical School-FAMERP/HB-FUNFARME, S\u00e3o Jos\u00e9 do Rio Preto-SP, Brazil"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rio de Janeiro", 
                        "country": "Brazil"
                    }, 
                    "name": "Nephrology Service, Bonsucesso General Hospital. Rio de Janeiro, Brazil"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "S\u00e3o Paulo", 
                        "country": "Brazil", 
                        "zip": "04038"
                    }, 
                    "name": "Renal Transplant Service, Hospital das Cl\u00ednicas, University of S\u00e3o Paulo School of Medicine, S\u00e3o Paulo, Brazil."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "S\u00e3o Paulo", 
                        "country": "Brazil", 
                        "zip": "04038"
                    }, 
                    "name": "Nephrology Division, Hospital do Rim, Federal University of S\u00e3o Paulo, Brazil"
                }
            }
        ], 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Outcomes of Planned Conversion From Tacrolimus to Sirolimus-based Immunosuppressive Regimen in de Novo Kidney Transplant Recipients", 
        "overall_official": [
            {
                "affiliation": "Nephrology Division, Hospital do Rim, Federal University of S\u00e3o Paulo, Brazil", 
                "last_name": "Helio T. Silva Junior, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Nephrology Division, Hospital do Rim, Federal University of S\u00e3o Paulo, Brazil", 
                "last_name": "Claudia R. Felipe, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Kidney & Pancreas Transplant Unit, Santa Casa de Misericordia, Porto Alegre, Brazil", 
                "last_name": "Valter D. Garcia, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Renal Transplant Service, Hospital das Cl\u00ednicas, University of S\u00e3o Paulo School of Medicine, S\u00e3o Paulo, Brazil", 
                "last_name": "Elias D. Neto, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Instituto de Urologia e Nefrologia & Medical School-FAMERP/HB-FUNFARME, S\u00e3o Jos\u00e9 do Rio Preto-SP, Brazil", 
                "last_name": "Mario A. Filho, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Hospital University Evang\u00e9lico de Curitiba, Curitiba, Parana, Brazil", 
                "last_name": "Fabiana LC Cortieri, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Nephrology Service, Bonsucesso General Hospital. Rio de Janeiro, Brazil", 
                "last_name": "Deise BM Carvalho, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Nephrology Division, Hospital do Rim, Federal University of S\u00e3o Paulo, Brazil", 
                "last_name": "Jose OM Pestana, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Renal Function calculated using the 4 variable MDRD formula", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01802268"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital do Rim e Hipertens\u00e3o", 
            "investigator_full_name": "Helio Tedesco Silva Junior", 
            "investigator_title": "PhD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Survival free from first treated biopsy confirmed acute rejection episodes (tBCAR) > IA according to Banff 1997 classification.", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Incidence of all treated acute rejections.", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Incidence and severity of all tBCAR.", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Patient and graft survival.", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Incidence of treatment discontinuation", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Incidence of adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Hospital do Rim e Hipertens\u00e3o", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Helio Tedesco Silva Junior", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}